MATCH Results: Implications for the Internist

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The long-awaited results of the Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack (MATCH) study, a large-scale trial undertaken to evaluate the safety and efficacy of clopidogrel + aspirin for secondary prevention of stroke, have been published. The efficacy of any antiplatelet therapy, including aspirin, is modest when it is used as monotherapy, and combination therapy with 2 antiplatelet agents has shown promise in reducing the risk for secondary stroke in patients who have had a previous transient ischemic attack (TIA) or ischemic stroke. However, unlike the Second European Stroke Prevention Study (ESPS-2), which demonstrated a significant reduction in risk for secondary stroke with aspirin + extended-release dipyridamole versus aspirin alone the results of the MATCH trial indicated that the reduction in risk achieved by adding aspirin to clopidogrel is not significantly greater than that achieved with clopidogrel alone. Furthermore, a significant increase in life-threatening bleeding complications was associated with the combination of clopidogrel + aspirin. Given these findings, clopidogrel + aspirin cannot be recommended at this time for the secondary prevention of stroke in patients who have had a previous ischemic stroke or TIA.

Original languageEnglish (US)
JournalAmerican Journal of Medicine
Volume119
Issue number6
DOIs
StatePublished - Jun 2006

Fingerprint

clopidogrel
Aspirin
Stroke
Transient Ischemic Attack
Risk Reduction Behavior
Secondary Prevention
Platelet Aggregation Inhibitors
Hemorrhage

Keywords

  • Antiplatelet
  • Aspirin
  • Clopidogrel
  • Extended-release dipyridamole
  • Secondary prevention
  • Stroke

ASJC Scopus subject areas

  • Nursing(all)

Cite this

MATCH Results : Implications for the Internist. / Lutsep, Helmi.

In: American Journal of Medicine, Vol. 119, No. 6, 06.2006.

Research output: Contribution to journalArticle

@article{1515255fe45743d6b71952f008df0322,
title = "MATCH Results: Implications for the Internist",
abstract = "The long-awaited results of the Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack (MATCH) study, a large-scale trial undertaken to evaluate the safety and efficacy of clopidogrel + aspirin for secondary prevention of stroke, have been published. The efficacy of any antiplatelet therapy, including aspirin, is modest when it is used as monotherapy, and combination therapy with 2 antiplatelet agents has shown promise in reducing the risk for secondary stroke in patients who have had a previous transient ischemic attack (TIA) or ischemic stroke. However, unlike the Second European Stroke Prevention Study (ESPS-2), which demonstrated a significant reduction in risk for secondary stroke with aspirin + extended-release dipyridamole versus aspirin alone the results of the MATCH trial indicated that the reduction in risk achieved by adding aspirin to clopidogrel is not significantly greater than that achieved with clopidogrel alone. Furthermore, a significant increase in life-threatening bleeding complications was associated with the combination of clopidogrel + aspirin. Given these findings, clopidogrel + aspirin cannot be recommended at this time for the secondary prevention of stroke in patients who have had a previous ischemic stroke or TIA.",
keywords = "Antiplatelet, Aspirin, Clopidogrel, Extended-release dipyridamole, Secondary prevention, Stroke",
author = "Helmi Lutsep",
year = "2006",
month = "6",
doi = "10.1016/j.amjmed.2005.10.047",
language = "English (US)",
volume = "119",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - MATCH Results

T2 - Implications for the Internist

AU - Lutsep, Helmi

PY - 2006/6

Y1 - 2006/6

N2 - The long-awaited results of the Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack (MATCH) study, a large-scale trial undertaken to evaluate the safety and efficacy of clopidogrel + aspirin for secondary prevention of stroke, have been published. The efficacy of any antiplatelet therapy, including aspirin, is modest when it is used as monotherapy, and combination therapy with 2 antiplatelet agents has shown promise in reducing the risk for secondary stroke in patients who have had a previous transient ischemic attack (TIA) or ischemic stroke. However, unlike the Second European Stroke Prevention Study (ESPS-2), which demonstrated a significant reduction in risk for secondary stroke with aspirin + extended-release dipyridamole versus aspirin alone the results of the MATCH trial indicated that the reduction in risk achieved by adding aspirin to clopidogrel is not significantly greater than that achieved with clopidogrel alone. Furthermore, a significant increase in life-threatening bleeding complications was associated with the combination of clopidogrel + aspirin. Given these findings, clopidogrel + aspirin cannot be recommended at this time for the secondary prevention of stroke in patients who have had a previous ischemic stroke or TIA.

AB - The long-awaited results of the Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack (MATCH) study, a large-scale trial undertaken to evaluate the safety and efficacy of clopidogrel + aspirin for secondary prevention of stroke, have been published. The efficacy of any antiplatelet therapy, including aspirin, is modest when it is used as monotherapy, and combination therapy with 2 antiplatelet agents has shown promise in reducing the risk for secondary stroke in patients who have had a previous transient ischemic attack (TIA) or ischemic stroke. However, unlike the Second European Stroke Prevention Study (ESPS-2), which demonstrated a significant reduction in risk for secondary stroke with aspirin + extended-release dipyridamole versus aspirin alone the results of the MATCH trial indicated that the reduction in risk achieved by adding aspirin to clopidogrel is not significantly greater than that achieved with clopidogrel alone. Furthermore, a significant increase in life-threatening bleeding complications was associated with the combination of clopidogrel + aspirin. Given these findings, clopidogrel + aspirin cannot be recommended at this time for the secondary prevention of stroke in patients who have had a previous ischemic stroke or TIA.

KW - Antiplatelet

KW - Aspirin

KW - Clopidogrel

KW - Extended-release dipyridamole

KW - Secondary prevention

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=33745003876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745003876&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2005.10.047

DO - 10.1016/j.amjmed.2005.10.047

M3 - Article

C2 - 16750967

AN - SCOPUS:33745003876

VL - 119

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 6

ER -